Iris Romero to Metformin
This is a "connection" page, showing publications Iris Romero has written about Metformin.
Connection Strength
3.087
-
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881.
Score: 0.595
-
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS One. 2016; 11(1):e0147145.
Score: 0.483
-
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60.
Score: 0.472
-
Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014 Dec; 135(3):614-21.
Score: 0.443
-
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10.
Score: 0.443
-
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
Score: 0.365
-
Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6.
Score: 0.158
-
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739.
Score: 0.127